Wall Street analysts expect TherapeuticsMD, Inc. (NASDAQ:TXMD) to post ($0.10) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for TherapeuticsMD’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.09). TherapeuticsMD reported earnings per share of ($0.21) during the same quarter last year, which suggests a positive year over year growth rate of 52.4%. The firm is scheduled to report its next earnings report before the market opens on Thursday, May 6th.
According to Zacks, analysts expect that TherapeuticsMD will report full-year earnings of ($0.41) per share for the current fiscal year, with EPS estimates ranging from ($0.50) to ($0.34). For the next financial year, analysts anticipate that the business will post earnings of ($0.16) per share, with EPS estimates ranging from ($0.25) to ($0.10). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, March 1st. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The company had revenue of $22.58 million for the quarter, compared to analyst estimates of $21.28 million.
A number of institutional investors and hedge funds have recently made changes to their positions in TXMD. BlackRock Inc. boosted its position in TherapeuticsMD by 14.6% during the fourth quarter. BlackRock Inc. now owns 21,419,273 shares of the company’s stock worth $25,918,000 after purchasing an additional 2,727,622 shares during the period. Morgan Stanley increased its position in shares of TherapeuticsMD by 6,296.3% during the 4th quarter. Morgan Stanley now owns 9,278,408 shares of the company’s stock valued at $11,227,000 after purchasing an additional 9,133,350 shares during the last quarter. Laurion Capital Management LP purchased a new stake in TherapeuticsMD in the fourth quarter worth approximately $4,006,000. Handelsbanken Fonder AB lifted its stake in shares of TherapeuticsMD by 30.0% in the 4th quarter. Handelsbanken Fonder AB now owns 3,250,000 shares of the company’s stock valued at $3,916,000 after acquiring an additional 750,000 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in TherapeuticsMD by 2.9% in the fourth quarter. Northern Trust Corp now owns 2,899,058 shares of the company’s stock worth $3,508,000 after acquiring an additional 82,860 shares during the period. 52.56% of the stock is owned by institutional investors.
Shares of TXMD traded up $0.04 on Tuesday, reaching $1.19. 7,491,110 shares of the company’s stock traded hands, compared to its average volume of 13,325,526. The stock’s 50 day simple moving average is $1.33 and its two-hundred day simple moving average is $1.41. The stock has a market cap of $467.90 million, a PE ratio of -1.64 and a beta of 2.19. TherapeuticsMD has a 52-week low of $1.05 and a 52-week high of $2.75.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Further Reading: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.